Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results

Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In.

On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein cholesterol after a single infusion. In an interim analysis of 35 participants, one dose of Verve-102 produced dose-dependent mean PCSK9 reductions ranging from 51% to 88%, from the 0.3 mg/kg dose to the 1.0 mg/kg dose. Corresponding mean LDL-C reductions were 9%, 44%, 45%, 33%, 51%, and 62%, with durability observed for up to 18 months after treatment.

Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results

On May 21, 2026, Wolfe Research said Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 results for retatrutide showing “class-leading” weight loss of up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants. Wolfe said the data also showed broad improvements in key cardiometabolic risk markers, further strengthening Eli Lilly’s GLP-1 franchise leadership and obesity therapeutics profile. Wolfe maintained an Outperform rating and a $1,350 price target on the shares.

Meanwhile, RBC Capital maintained an Outperform rating and a $1,250 price target on Eli Lilly and Company (NYSE:LLY). RBC said the retatrutide Phase 3 trial was a clean win, citing a clean safety profile and best-in-class efficacy across all doses. RBC said it is modeling a retatrutide launch in 2027, 2030 sales of $4.9B, and 2034 sales of $11.0B with a 70% probability of success.

Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products internationally.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.